期刊文献+

SETDB1的生物学功能及其在疾病发生中的作用机理研究进展 被引量:1

Advances of Biological Function and Mechanisms of SETDB1 in the Disease Pathogenesis
原文传递
导出
摘要 组蛋白甲基转移酶家族是表观遗传调控的关键参与者。SET结构域分支型1(SETDB1)是组蛋白甲基转移酶家族的成员,其在组蛋白H3上甲基化赖氨酸9位点,在涉及转录抑制和常染色体基因沉默的生物网络中显示多重功能。该综述总结了SETDB1的结构和功能,以及相关疾病的发生和发展所涉及的分子机制的最新进展,以期对疾病诊断和临床治疗有所帮助。 The histone methyltransferase family is the crucial participant in epigenetic regulation.SET domain bifurcated 1(SETDB1),a member of the histone methyltransferase family,methylates lysine 9 position on histone H3 and shows multiply function in biological networks involving in transcriptional inhibition and autosomal gene silencing.This review summarizes the structure and function of SETDB1,the latest advances in the molecular mechanisms involved in the development and progression of related diseases,which highlight novel strategies for theoretical guidance and clinical treatment.
作者 屠雨青 朱陈念慈 陈佳明 吴俊伟 欧文斌 Tu Yuqing;Zhu Chennianci;Chen Jiaming;Wu Junwei;Ou Wen-Bin(Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine,Zhejiang Sci-Tech University,Hangzhou 310018,China)
出处 《中国细胞生物学学报》 CAS CSCD 2019年第3期523-531,共9页 Chinese Journal of Cell Biology
基金 国家自然科学基金(批准号:81728012) 浙江省自然科学基金项目(批准号:LY18H160065) 浙江理工大学科研启动基金(批准号:14042107-Y) 国家级大学生创新创业训练计划项目和浙江省新苗计划资助的课题~~
关键词 SETDB1 组蛋白甲基转移酶 多功能 发病机理 SETDB1 histone methyltransferase multiply function pathogenesis
  • 相关文献

参考文献1

二级参考文献31

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012,62: 283-98.
  • 2Roberts WB, Han M. Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Sure Oncol 2009,18: 268-74.
  • 3Saad F, Hotte S, North S, Eigl B, Chi K, et al. Randomized phase Ⅱ trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Research 2011,17: 5765-73.
  • 4Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, etal. Gene expression analysis of prostate cancers. Mol Carcinog 2002,33: 25-35.
  • 5Yu YP, Song C, Tseng G, Ren BG, LaFramboise W, etal. Genome abnormalities precede prostate cancer and predict clinical relapse. Am J Patho12012,180: 2240-8.
  • 6Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009, 150:3991-4002.
  • 7Jeronimo C, Henrique R. Epigenetic biomarkers in urological tumors: a systematic review. Cancer Lett 2011.
  • 8Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007,128: 707-19.
  • 9Klose R J, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Bio 2007,8: 307-18.
  • 10Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009,10: 295-304.

共引文献6

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部